多烯磷脂酰胆碱联合二甲双胍治疗对非酒精性脂肪性肝病患者肝纤维化、血浆抵抗素与胰岛素抵抗的影响

易默; 周健; 史丽萍; 吴友伟

doi:10.3969/j.issn.1671-038X.2017.09.01

多烯磷脂酰胆碱联合二甲双胍治疗对非酒精性脂肪性肝病患者肝纤维化、血浆抵抗素与胰岛素抵抗的影响

- 陕西省人民医院消化内二科, 陕西西安 710068
基金项目:
陕西省自然科学基础研究项目 (No:2014JM4189)

详细信息

作者简介:
易默,女,硕士研究生,主治医师,研究方向:消化内科疾病的诊治

通讯作者: 易默,E-mail:124375121@qq.com

中图分类号: R575

收稿日期: 2017-07-10

Effects of polyene phosphatidylcholine combined with metformin on liver fibrosis,plasma resistin and insulin resistance in patients with nonalcoholic fatty liver disease

- Second Department of Gastroenterology, Shanxi Provincial People's Hospital, Xi'an 710068, China

More Information

Corresponding author: YI Mo, E-mail: 124375121@qq.com

Received Date: 10 July 2017

摘要

摘要: [目的]研究多烯磷脂酰胆碱联合二甲双胍治疗对非酒精性脂肪性肝病(NAFLD)患者肝纤维化,血浆抵抗素以及胰岛素抵抗的影响。[方法]选取我院在2015年1月~2017年1月收治的122例NAFLD患者,将患者按照不同治疗方式分成2组(每组61例),对照组患者采用多烯磷脂酰胆碱,观察组患者采用多烯磷脂酰胆碱联合二甲双胍治疗。观察不同治疗方式对患者肝纤维化指标、血浆抵抗素以及胰岛素抵抗的影响。[结果]治疗后观察组患者各项肝纤维化指标为[(90.36±27.54)mg/L、(85.48±26.57)μg/L、(45.21±24.14)μg/L、(85.49±26.84)μg/L],显著低于对照组肝纤维化各项指标值[(144.36±48.75)mg/L、(114.31±35.24)μg/L、(76.24±37.57)μg/L、(123.51±36.58)μg/L、(P<0.05)];2组患者治疗前后Wt、BMI、WC、TG、TC、HDL-C、LDL-C变化情况比较差异无统计学意义(P>0.05);FPG、FINS、ALT、AST、Resistin、HOMA-IR各指标在治疗前比较差异无统计学意义(P>0.05),治疗后观察组患者各指标值为[(4.11±1.14)mmol/L、(8.27(3.21~11.84))mIU/L、(31.51±6.47)U/L、(29.31±7.54)U/L、(12.54±3.14)μg/L、(2.64(1.79~5.12))],显著低于对照组各指标值[(6.23±2.34)mmol/L、(9.95(3.30~11.81))mIU/L、(52.61±8.76)U/L、(37.54±8.21)U/L、(16.62±4.48)μg/L、(3.24(1.71~4.87)),(P<0.05)],2组患者治疗期间未出现不良反应情况。[结论]多烯磷脂酰胆碱联合二甲双胍治疗具有缓解NAFLD患者肝纤维化作用,改善NAFLD患者胰岛素抵抗程度以及降低NAFLD患者血浆抵抗素的表达水平。
- 多烯磷脂酰胆碱 /
- 二甲双胍 /
- 非酒精性脂肪性肝病 /
- 肝纤维化 /
- 血浆抵抗素
Abstract: [Objective]To investigate the effect of polyene phosphatidylcholine combined with metformin on liver fibrosis,plasma resistin and insulin resistance in patients with nonalcoholic fatty liver disease(NAFLD).[Methods]A total of 122 cases with NAFLD in our hospital from January 2015 to January 2017 were selected and according to the different treatment methods divided into two groups(61 cases in each group).The control group was treated with polyene phosphatidylcholine and the observation group treated with polyene phosphatidylcholine combined with metformin.The effects of different treatment methods on the indexes of liver fibrosis,plasma resistin and insulin resistance were observed and compared.[Results]After treatment,the hepatic fibrosis index in the observation group were[(90.36±27.54)mg/L,(85.48±26.57)g/L,(45.21±24.14)g/L,(85.49±26.84)g/L],which were significantly lower than that in the control group[(144.36±48.75)mg/L,(114.31±35.24)g/L,(76.24±37.57)g/L,(123.51±36.58)g/L](P<0.05).The levels of Wt,BMI,WC,TG,TC,HDL-C and LDL-C in two groups of patients before and after treatment were no significant changes(P>0.05).There was no significant difference between two groups about the indexes of FPG,FINS,ALT,AST,resistin,HOMA-IR before treatment(P>0.05).After treatment,the each index value of the observation group were[(4.11±1.14)mmol/L,(8.27(3.21~11.84))mIU/L,(31.51±6.47)U/L,(29.31±7.54)U/L,(12.54±3.14)g/L,(2.64(1.79~5.12))],which was significantly lower than that in the control group[(6.23±2.34)mmol/L,(9.95(3.30~11.81))mIU/L,(52.61±8.76)U/L,(37.54±8.21)U/L,(16.62±4.48)g/L,(3.24(1.71~4.87))](P<0.05).There was no adverse reactions during treatment in two groups.[Conclusion]Polyene phosphatidylcholine combined with metformin in the treatment of patients with NAFLD can alleviate hepatic fibrosis,improve insulin resistance and reduce the level of plasma resistin.
- Polyene phosphatidylcholine /
- Metformin /
- Nonalcoholic fatty liver disease /
- Liver fibrosis /
- Plasma resistin

HTML全文

参考文献(21)

[1]	范建高.非酒精性脂肪性肝病的研究现状与展望[J].临床肝胆病杂志, 2015, 31 (7):999-1001.
[2]	Lonardo A, Bellentani S, Argo C K, et al.Epidemiological modifiers of non-alcoholic fatty liver disease:Focus on high-risk groups[J].Digestive&Liver Disease, 2015, 47 (12):997-1006.
[3]	荀运浩, 施军平.2014年非酒精性脂肪性肝病诊治进展[J].实用肝脏病杂志, 2015, 18 (1):6-9.
[4]	吴莘, 袁方, 黄欣, 等.多烯磷脂酰胆碱联合甘草酸二铵治疗非酒精性脂肪性肝病疗效观察[J].中华消化杂志, 2015, 35 (6):411-412.
[5]	张淑波, 丁婷, 陈文平.二甲双胍对非酒精性脂肪性肝病氧化应激的影响[J].西北药学杂志, 2015, 30 (2):361-362.
[6]	吕梅, 郎旭龙, 王飞, 等.微生态制剂改善非酒精性脂肪性肝病患者胰岛素抵抗的临床研究[J].现代生物医学进展, 2016, 16 (6):1073-1075.
[7]	梁淑文, 王晓英, 屈昌民, 等.非酒精性脂肪性肝病患者胰岛素抵抗与肠道菌群失调相关性研究[J].中国医药, 2016, 11 (1):83-86.
[8]	中华医学会肝病学分会脂肪肝与酒精性肝病学组.中国非酒精性肝病诊疗指南 (2010年修订版)[J].中华肝脏病杂志 (电子版), 2010, 18 (3):163-166.
[9]	Adams L A, Adams L A.Nonalcoholic Fatty Liver Disease and Diabetes Mellitus[J].Endocrine Research, 2015, 32 (3):59-69.
[10]	张秋楠, 肖英, 苗瑞新, 等.非酒精性脂肪性肝病患者肠道菌群变化与胰岛素抵抗指数、肿瘤坏死因子α和白细胞介素6的相关性分析[J].临床肝胆病杂志, 2015, 31 (7):1078-1081.
[11]	胡义扬.中医药治疗非酒精性脂肪性肝病的优势与展望[J].世界中医药, 2015, 10 (2):149-152.
[12]	唐纪兰, 文新年, 韦凌云, 等.吡格列酮对非酒精性脂肪性肝病患者胰岛素抵抗及内皮功能的影响[J].中华实用诊断与治疗杂志, 2015, 29 (3):303-304.
[13]	张秋瓒, 王艳荣, 刘应莉, 等.替米沙坦对非酒精性脂肪性肝炎大鼠胰岛素抵抗及抵抗素的影响[J].中华肝脏病杂志, 2015, 23 (4):281-285.
[14]	熊鹰, 张声生, 周滔, 等.调肝理脾方对非酒精性脂肪肝患者脂联素、抵抗素及肿瘤坏死因子α的影响[J].中华中医药杂志, 2015, 30 (12):4419-4422.
[15]	肖丽萍, 余新沛, 刘岗, 等.多烯磷脂酰胆碱联合维生素E治疗非酒精性脂肪性肝炎合并2型糖尿病患者效果研究[J].实用肝脏病杂志, 2016, 19 (2):172-175.
[16]	高鹰, 周颖.胆宁片联合多烯磷脂酰胆碱胶囊治疗非酒精性脂肪肝的疗效观察[J].现代药物与临床, 2017, 32 (3):464-467.
[17]	谢双林.多烯磷脂酰胆碱联合维生素E治疗非酒精性脂肪肝的疗效及安全性评价[J].中国临床药理学杂志, 2015, 24 (9):712-714.
[18]	王倩, 吴鹏波, 柳健, 等.二甲双胍在非酒精性脂肪性肝病治疗作用中的研究进展[J].胃肠病学和肝病学杂志, 2017, 26 (3):348-351.
[19]	郑仲萍, 田峰, 郑志刚, 等.二甲双胍联用六味地黄丸对新诊断2型糖尿病合并非酒精性脂肪肝疗效观察[J].辽宁中医药大学学报, 2015, 17 (7):123-126.
[20]	全晓红, 李秀丽, 叶冬梅, 等.非酒精性脂肪肝患者血清抵抗素与胰岛素抵抗关系研究[J].中华实用诊断与治疗杂志, 2015, 29 (4):372-374.
[20]	熊鹰, 张声生, 周滔, 等.调肝理脾方对非酒精性脂肪肝患者脂联素、抵抗素及肿瘤坏死因子α的影响[J].中华中医药杂志, 2015, 30 (12):4419-4422.